1. Home
  2. KLRS vs ZVIA Comparison

KLRS vs ZVIA Comparison

Compare KLRS & ZVIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KLRS
  • ZVIA
  • Stock Information
  • Founded
  • KLRS 2019
  • ZVIA 2007
  • Country
  • KLRS United States
  • ZVIA United States
  • Employees
  • KLRS N/A
  • ZVIA N/A
  • Industry
  • KLRS Biotechnology: Biological Products (No Diagnostic Substances)
  • ZVIA Beverages (Production/Distribution)
  • Sector
  • KLRS Health Care
  • ZVIA Consumer Staples
  • Exchange
  • KLRS Nasdaq
  • ZVIA Nasdaq
  • Market Cap
  • KLRS 129.0M
  • ZVIA 142.5M
  • IPO Year
  • KLRS N/A
  • ZVIA 2021
  • Fundamental
  • Price
  • KLRS $3.89
  • ZVIA $2.81
  • Analyst Decision
  • KLRS Buy
  • ZVIA Hold
  • Analyst Count
  • KLRS 1
  • ZVIA 3
  • Target Price
  • KLRS N/A
  • ZVIA $2.58
  • AVG Volume (30 Days)
  • KLRS 62.9K
  • ZVIA 565.8K
  • Earning Date
  • KLRS 05-19-2025
  • ZVIA 05-07-2025
  • Dividend Yield
  • KLRS N/A
  • ZVIA N/A
  • EPS Growth
  • KLRS N/A
  • ZVIA N/A
  • EPS
  • KLRS N/A
  • ZVIA N/A
  • Revenue
  • KLRS N/A
  • ZVIA $154,273,000.00
  • Revenue This Year
  • KLRS N/A
  • ZVIA $5.70
  • Revenue Next Year
  • KLRS N/A
  • ZVIA $7.10
  • P/E Ratio
  • KLRS N/A
  • ZVIA N/A
  • Revenue Growth
  • KLRS N/A
  • ZVIA N/A
  • 52 Week Low
  • KLRS $4.19
  • ZVIA $0.62
  • 52 Week High
  • KLRS $24.15
  • ZVIA $4.99
  • Technical
  • Relative Strength Index (RSI)
  • KLRS N/A
  • ZVIA 64.11
  • Support Level
  • KLRS N/A
  • ZVIA $1.97
  • Resistance Level
  • KLRS N/A
  • ZVIA $3.20
  • Average True Range (ATR)
  • KLRS 0.00
  • ZVIA 0.21
  • MACD
  • KLRS 0.00
  • ZVIA 0.07
  • Stochastic Oscillator
  • KLRS 0.00
  • ZVIA 73.72

About KLRS Kalaris Therapeutics Inc. Common Stock

Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.

About ZVIA Zevia PBC

Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.

Share on Social Networks: